Piramal Imaging Highlights New Data for Beta-Amyloid Imaging Agent Florbetaben F18 at EANM 2013

BERLIN, BOSTON and MUMBAI, India, Oct. 17, 2013 /PRNewswire/ -- Piramal Imaging announced today that results from four studies evaluating the Company's PET amyloid imaging agent, florbetaben F18^*, will be presented at the 2013 Annual Congress of the European Association of Nuclear Medicine (EANM), which will be held in Lyon, France from October 19-23, 2013.

(Logo: http://photos.prnewswire.com/prnh/20130507/NE09018LOGO )

Florbetaben is currently being reviewed by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for use in the visual detection of beta-amyloid in the brains of adults with cognitive impairment who are being evaluated for Alzheimer's disease (AD) and other causes of cognitive decline.

"More than six million people in Europe suffer from Alzheimer's disease and as this number grows, so does the need for improved diagnosis," said Dr. Ludger Dinkelborg, Director of the Board, Piramal Imaging SA. "The acceptance of four oral scientific presentations at EANM demonstrates the interest in the florbetaben F18 development program and its potential role in providing physicians with data to increase diagnostic accuracy of Alzheimer's disease." 

Presentations highlighting florbetaben include:

• Correction of partial volume effects in an Alzheimer's disease mouse model using [18F] florbetaben PET [OP383] 
  Session: Featured – Neurosciences: Amyloid Quantification 
  Monday, October 21, 2013, 16:45-16:56, Room: Bellecour 1/2/3

• Evaluation of software tools for automated identification of neuroanatomical structures in beta-amyloid PET imaging to diagnose Alzheimer's disease [OP384] 
  Session: Featured – Neurosciences: Amyloid Quantification 
  Monday, October 21, 2013, 16:56-17:07, Room: Bellecour 1/2/3

• Automated analysis of 18F-florbetaben PET scans [OP385]
  Session: 1004 Featured – Neurosciences: Amyloid Quantification 
  Monday, October 21, 2013, 17:07-17:18, Room: Bellecour 1/2/3

• Beta-Amyloid PET Imaging in Alzheimer's Disease in a Close to Clinical Routine Situation – Results of a Multi-center Phase 2 Trial [OP715] 
  Parallel Session: Neurosciences: Dementia 
  Wednesday, October 23, 2013, 10:00-10:11, Room: Salon Pasteur

To learn more about Piramal Imaging, visit IBA's booth #349 at EANM.

NOTE TO EDITORS: All data is embargoed until the date/time of presentation.

About Piramal Imaging SA

Piramal Imaging SA, a division of Piramal Enterprises, Ltd., was formed in 2012 with the acquisition of the molecular imaging research and development portfolio of Bayer Pharma AG. By developing novel PET tracers for molecular imaging, Piramal Imaging is focusing on a key field of modern medicine. Piramal Imaging strives to be a leader in the Molecular Imaging field by developing innovative products that improve early detection and characterization of chronic and life threatening diseases leading to better therapeutic outcomes and improved quality of life. For more information please go to http://imaging.piramalenterprises.com.

About Piramal Enterprises Ltd.

Piramal Enterprises is one of India's largest diversified companies, with a presence in pharmaceutical, financial services and information management sectors. Piramal Enterprises had consolidated revenues of over $650 million in FY2013. In the pharmaceutical space, PEL is one of leading custom manufacturing player globally, has presence in the global critical care segment with a portfolio of inhalation and injectable anesthetics and its OTC business is ranked no. 7 in India. PEL is also engaged in drug discovery & research and has strong pipeline of development products. In the financial services space, PEL has a real estate focused PE fund – Indiareit and a NBFC that is focused on lending to real estate and education sector. PEL's information management business, Decision Resources Group is a leading provider of information based services to the healthcare industry.

^*Florbetaben is an investigational PET amyloid imaging agent currently under review by the U.S. Food and Drug Administration and the European Medicines Agency.

For media inquiries, please contact:  

Tammy Best 
Marketing Communications Manager 
Piramal Enterprises – Imaging Division 
Contact: +1 617-725-0070 x408 
tammy.best@piramal.com

Akansha Pradhan 
Corporate Communications 
Piramal Group 
Contact: +91 3351 4082 
akansha.pradhan@piramal.com